Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPR206 Intrapulmonary Pharmacokinetics in Healthy Volunteers
NCT04868292Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SPR206 in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP) and Gram-negative bacterial infection, sponsored by Spero Therapeutics. Primary endpoints: Area under the concentration-time curve from time 0 to 8 hours, Maximum observed concentration at 8 hours and 2 more. Started Jun 2021; status: completed.
02
Drugs
SPR206
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT04868292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868292.